CONVERT-TDD: Intrathecal Morphine Compared to Conventional Medical Management for Pain Control and Opioid-related Side Effects
Study Details
Study Description
Brief Summary
This study compares two different ways to treat pain. The two ways are:
-
continuing to take current pain medication(s) or
-
receiving morphine, a pain medication from a drug pump (a system to deliver drug to your body) that is implanted.
None of the procedures or products used in this study are experimental. The length the study will be about 25 weeks (between 5½ to 6½ months). The purpose of this study is to compare pain and opioid side effects between people who get a drug pump and people who do not get a drug pump that will stay on their current pain medication treatment.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
This was a randomized, controlled, open-label, multi-center, prospective post-market study to assess pain control and opioid-related side effects following a route of delivery change to low dose IT morphine therapy from systemic opioid therapy. Subjects with nonmalignant, chronic, intractable pain who were experiencing inadequate pain relief and/or intolerable side effects from systemic opioid therapy receiving ≤300 mg/day morphine equivalent dose were eligible for screening. Additionally, the subjects had no known history of sleep apnea and were candidates for IT morphine administration via the SynchroMed Infusion System. Subjects must not have previously undergone an intrathecal/epidural trial for pump infusion therapy.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: IT group (Intrathecal Morphine Sulfate) SynchroMed Infusion System and Intrathecal Morphine Sulfate |
Device: SynchroMed Infusion System and Intrathecal Morphine Sulfate
Following a successful test of Intrathecal Morphine Sulfate, subjects will undergo surgery to implant the drug pump (SynchroMed Infusion System) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control.
Other Names:
|
| Other: Conventional Medical Management Conventional Medicine, and then SynchroMed Infusion System and Intrathecal Morphine Sulfate |
Device: SynchroMed Infusion System and Intrathecal Morphine Sulfate
Following a successful test of Intrathecal Morphine Sulfate, subjects will undergo surgery to implant the drug pump (SynchroMed Infusion System) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control.
Other Names:
Other: Conventional Medicine
Subjects will continue to use pain medications as prescribed by their doctor.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Clinical Success [3 Month]
Determine the proportion of subjects with clinical success based on changes in pain intensity (Numerical Pain Rating Scale: NPRS) and opioid-related Common Toxicity Criteria for Adverse Events (CTCAE) from the National Cancer Institute (NCI).
Secondary Outcome Measures
- Pain Assessment [3 Month]
Compare changes from Baseline to Month 3 between the IT group and CMM group in Numeric Pain Rating Scale (NPRS). The scale measures pain intensity. Using NPRS, a pain score ranging from 0 (no pain) to 10 (pain as bad as you can imagine) is recorded on a subject diary twice daily for 5 days before a study visit. The score for each visit is calculated as the mean pain of the 5 diary days morning and evening scores. For each subject, the change in pain will be calculated as the mean pain score at Month 3 minus the mean pain score at Baseline. A negative change value represents a lowering of the pain score (an improvement, or reduction in pain).
- Opioid-Related Side Effects [3 Month]
Summarize the changes from Baseline to Month 3 between the IT group and CMM group in Common Terminology Criteria for Adverse Events (CTCAE) toxicity score. (from the National Cancer Institute) A subset of 23 specific items of the CTCAE v4.03 were evaluated. The subset was chosen as these criteria were most related to opioid side effects that are of interest in this study. The investigator scored the assessment at each visit. The total score for a visit is based on the sum of 23 individual CTCAE's. The individual scales have a range of 0 to 2, 0 to 3, or 0 to 5 and the total score ranges from 0 (best case) to 90 (worst case). For each subject, the change in toxicity will be calculated as the total toxicity score at Month 3 minus the total toxicity score at Baseline. A negative change value represents a lowering of the subjects toxicity score (an improvement, or reduction in toxicity).
Other Outcome Measures
- Sleep Assessment [3 Month]
Compare changes from Baseline to Month 3 between the IT group and CMM group for Apnea-Hypopnea Index (AHI). The AHI was collected via overnight sleep lab polysomnography. The AHI is an index used to indicate the severity of sleep apnea. It is represented by the number of apnea and hypopnea events per hour of sleep. The AHI values for adults are categorized as Normal: AHI<5, Mild sleep apnea: 5≤AHI<15, Moderate sleep apnea: 15≤AHI<30, Severe sleep apnea: AHI≥30. For each subject, the change in AHI will be calculated as the AHI at Month 3 minus the AHI at Baseline. A negative change value represents a lowering of the subjects AHI (an improvement, or reduction in sleep apnea).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Signed and dated Medtronic/IRB approved Informed Consent Form and HIPAA Authorization prior to any study procedures being performed
-
Willing and able to attend visits and comply with the study protocol
-
Willing and able to abstain from alcohol consumption for the study duration
-
At least 18 years of age
-
Male or non-pregnant, non-lactating female
-
Currently receiving </= 300 mg/day morphine equivalent of systemic opioids at screening
-
Used a stable dose of opioids (no change in type or prescribed frequency or dose) for 30 days prior to the Screening as documented in the medical history
-
Used chronic systemic opioids for at least 6 months prior to Screening as documented in medical history
Per investigator's medical assessment and the subject's medical history, the subject is/has:
-
A new candidate for chronic intrathecal drug therapy (including no prior intrathecal/epidural trial for pump infusion therapy)
-
A diagnosis of nonmalignant, chronic intractable pain as documented in the medical history
-
Medically stable and able to undergo surgery for implantation of the SynchroMed Infusion System
-
Completed a psychological evaluation within 6 months prior to Screening
Exclusion Criteria:
-
Psychological or other health conditions, financial, and/or legal concerns (within 3 months prior to Screening) that would interfere with the subject's ability to fulfill the requirements of the protocol as per the investigator's opinion
-
A history of alcohol abuse or any illicit drug use within 2 years prior to Screening
-
A positive urine test for illicit drugs at Screening (Exception: If subject has a physician's prescription for an illicit drug; for example, medical marijuana)
-
Known diagnosis of moderate to severe sleep apnea.
-
Prescribed Continuous Positive Airway Pressure (CPAP), Adaptive Servo-Ventilation (ASV) therapy or an oral appliance prescribed for the treatment of moderate to severe sleep apnea (current or previous history)
-
An active malignancy or has been diagnosed with cancer and has not been in remission for at least 1 year prior to screening
-
An implanted electrical stimulation device(s) or if the subject is expected to require one of these during the course of the study
-
Planned to enroll or is currently enrolled in another investigational drug or investigational medical device study or has participated in an investigational drug or medical device study within 30 days prior to Screening
Prior to Randomization, a subject will be excluded if:
-
Diary does not meet compliance
-
Mean diary-reported 12-hour NPRS < 6 (on 0 to 10 scale, as reported over 5 days)
-
Positive urine test for alcohol at Baseline
-
Negative urine test for opioids at Baseline
-
Baseline sleep study (PSG) with SaO2 <=80% for >= 5 consecutive minutes, and/or an Apnea-Hypopnea Index (AHI) >=15.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Pain Management Services PC | Homewood | Alabama | United States | 35209 |
| 2 | Napa Pain Institute and Neurovations | Napa | California | United States | 94558 |
| 3 | IPM Medical Group (Interventional Pain Medical Group) | Walnut Creek | California | United States | 94598 |
| 4 | Compass Research | Orlando | Florida | United States | 32806 |
| 5 | The Center for Clinical Research | Winston-Salem | North Carolina | United States | 27103 |
| 6 | University of Virginia Pain Management Center | Charlottesville | Virginia | United States | 22908-0710 |
Sponsors and Collaborators
- MedtronicNeuro
Investigators
- Study Director: CONVERT TDD Clinical Research Study Team, MedtronicNeuro
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 1664 - CONVERT-TDD
Study Results
Participant Flow
| Recruitment Details | Seven participants were enrolled (consented). |
|---|---|
| Pre-assignment Detail | Of the 7 participants that were enrolled, 3 met the randomization eligibility and were randomized to the IT Group. Of the 3 participants randomized, 2 were implanted. |
| Arm/Group Title | IT Group (SynchroMed/Intrathecal Morphine Sulfate) | Conventional Medical Management |
|---|---|---|
| Arm/Group Description | Subjects randomized to the IT group (Intrathecal morphine sulfate/SynchroMed Infusion System) will have a test injection or infusion of intrathecal morphine to check for pain control and make sure there are no negative reactions. If the test is successful, subjects in the IT group will have a pump and spinal catheter implanted. These subjects will stop using all other pain medications and start using only intrathecal morphine for pain control. SynchroMed Infusion System and Intrathecal Morphine Sulfate: Following a successful intrathecal test of morphine, IT morphine subjects will undergo surgery to implant the drug pump (SynchroMed) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control. | Subjects randomized to the CMM group will continue to use pain medications as prescribed by their doctor. Subjects randomized to CMM will be offered the option of pump implant following completion of the 3-month visit. |
| Period Title: Overall Study | ||
| STARTED | 3 | 0 |
| COMPLETED | 2 | 0 |
| NOT COMPLETED | 1 | 0 |
Baseline Characteristics
| Arm/Group Title | IT Group (SynchroMed/Intrathecal Morphine Sulfate) | Conventional Medical Management | Total |
|---|---|---|---|
| Arm/Group Description | Subjects randomized to the IT group (Intrathecal morphine sulfate/SynchroMed Infusion System) will have a test injection or infusion of intrathecal morphine to check for pain control and make sure there are no negative reactions. If the test is successful, subjects in the IT group will have a pump and spinal catheter implanted. These subjects will stop using all other pain medications and start using only intrathecal morphine for pain control. SynchroMed Infusion System and Intrathecal Morphine Sulfate: Following a successful intrathecal test of morphine, IT morphine subjects will undergo surgery to implant the drug pump (SynchroMed) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control. | Subjects randomized to the CMM group will continue to use pain medications as prescribed by their doctor. Subjects randomized to CMM will be offered the option of pump implant following completion of the 3-month visit. | Total of all reporting groups |
| Overall Participants | 3 | 0 | 3 |
| Age (years) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [years] |
56.2
(11.8)
|
56.2
(11.8)
|
|
| Sex: Female, Male (Count of Participants) | |||
| Female |
2
66.7%
|
2
Infinity
|
|
| Male |
1
33.3%
|
1
Infinity
|
|
| Baseline patient-reported pain diary score (units on a scale) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [units on a scale] |
7.0
(1.4)
|
7.0
(1.4)
|
|
| Baseline 23-item toxicity score (units on a scale) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [units on a scale] |
8.7
(3.8)
|
8.7
(3.8)
|
|
Outcome Measures
| Title | Clinical Success |
|---|---|
| Description | Determine the proportion of subjects with clinical success based on changes in pain intensity (Numerical Pain Rating Scale: NPRS) and opioid-related Common Toxicity Criteria for Adverse Events (CTCAE) from the National Cancer Institute (NCI). |
| Time Frame | 3 Month |
Outcome Measure Data
| Analysis Population Description |
|---|
| 2 of the 3 randomized participants did not complete the follow-up or provide outcome information. As there was only 1 participant that completed the primary outcome assessment, no statistical analysis will be presented. |
| Arm/Group Title | IT Group (SynchroMed/Intrathecal Morphine Sulfate) | Conventional Medical Management |
|---|---|---|
| Arm/Group Description | Subjects randomized to the IT group (Intrathecal morphine sulfate/SynchroMed Infusion System) will have a test injection or infusion of intrathecal morphine to check for pain control and make sure there are no negative reactions. If the test is successful, subjects in the IT group will have a pump and spinal catheter implanted. These subjects will stop using all other pain medications and start using only intrathecal morphine for pain control. SynchroMed Infusion System and Intrathecal Morphine Sulfate: Following a successful intrathecal test of morphine, IT morphine subjects will undergo surgery to implant the drug pump (SynchroMed) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control. | Subjects randomized to the CMM group will continue to use pain medications as prescribed by their doctor. Subjects randomized to CMM will be offered the option of pump implant following completion of the 3-month visit. |
| Measure Participants | 1 | 0 |
| Number [participants] |
1
33.3%
|
| Title | Pain Assessment |
|---|---|
| Description | Compare changes from Baseline to Month 3 between the IT group and CMM group in Numeric Pain Rating Scale (NPRS). The scale measures pain intensity. Using NPRS, a pain score ranging from 0 (no pain) to 10 (pain as bad as you can imagine) is recorded on a subject diary twice daily for 5 days before a study visit. The score for each visit is calculated as the mean pain of the 5 diary days morning and evening scores. For each subject, the change in pain will be calculated as the mean pain score at Month 3 minus the mean pain score at Baseline. A negative change value represents a lowering of the pain score (an improvement, or reduction in pain). |
| Time Frame | 3 Month |
Outcome Measure Data
| Analysis Population Description |
|---|
| 2 of the 3 randomized participants did not complete the follow-up or provide outcome information. As there was only 1 participant that completed the secondary outcome assessment, no statistical analysis will be presented. |
| Arm/Group Title | IT Group (SynchroMed/Intrathecal Morphine Sulfate) | Conventional Medical Management |
|---|---|---|
| Arm/Group Description | Subjects randomized to the IT group (Intrathecal morphine sulfate/SynchroMed Infusion System) will have a test injection or infusion of intrathecal morphine to check for pain control and make sure there are no negative reactions. If the test is successful, subjects in the IT group will have a pump and spinal catheter implanted. These subjects will stop using all other pain medications and start using only intrathecal morphine for pain control. SynchroMed Infusion System and Intrathecal Morphine Sulfate: Following a successful intrathecal test of morphine, IT morphine subjects will undergo surgery to implant the drug pump (SynchroMed) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control. | Subjects randomized to the CMM group will continue to use pain medications as prescribed by their doctor. Subjects randomized to CMM will be offered the option of pump implant following completion of the 3-month visit. |
| Measure Participants | 1 | 0 |
| Mean (Standard Deviation) [units on a scale] |
-3.3
(0)
|
| Title | Opioid-Related Side Effects |
|---|---|
| Description | Summarize the changes from Baseline to Month 3 between the IT group and CMM group in Common Terminology Criteria for Adverse Events (CTCAE) toxicity score. (from the National Cancer Institute) A subset of 23 specific items of the CTCAE v4.03 were evaluated. The subset was chosen as these criteria were most related to opioid side effects that are of interest in this study. The investigator scored the assessment at each visit. The total score for a visit is based on the sum of 23 individual CTCAE's. The individual scales have a range of 0 to 2, 0 to 3, or 0 to 5 and the total score ranges from 0 (best case) to 90 (worst case). For each subject, the change in toxicity will be calculated as the total toxicity score at Month 3 minus the total toxicity score at Baseline. A negative change value represents a lowering of the subjects toxicity score (an improvement, or reduction in toxicity). |
| Time Frame | 3 Month |
Outcome Measure Data
| Analysis Population Description |
|---|
| 2 of the 3 randomized participants did not complete the follow-up or provide outcome information. As there was only 1 participant that completed the secondary outcome assessment, no statistical analysis will be presented. |
| Arm/Group Title | IT Group (SynchroMed/Intrathecal Morphine Sulfate) | Conventional Medical Management |
|---|---|---|
| Arm/Group Description | Subjects randomized to the IT group (Intrathecal morphine sulfate/SynchroMed Infusion System) will have a test injection or infusion of intrathecal morphine to check for pain control and make sure there are no negative reactions. If the test is successful, subjects in the IT group will have a pump and spinal catheter implanted. These subjects will stop using all other pain medications and start using only intrathecal morphine for pain control. SynchroMed Infusion System and Intrathecal Morphine Sulfate: Following a successful intrathecal test of morphine, IT morphine subjects will undergo surgery to implant the drug pump (SynchroMed) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control. | Subjects randomized to the CMM group will continue to use pain medications as prescribed by their doctor. Subjects randomized to CMM will be offered the option of pump implant following completion of the 3-month visit. |
| Measure Participants | 1 | 0 |
| Mean (Standard Deviation) [units on a scale] |
-6
(0)
|
| Title | Sleep Assessment |
|---|---|
| Description | Compare changes from Baseline to Month 3 between the IT group and CMM group for Apnea-Hypopnea Index (AHI). The AHI was collected via overnight sleep lab polysomnography. The AHI is an index used to indicate the severity of sleep apnea. It is represented by the number of apnea and hypopnea events per hour of sleep. The AHI values for adults are categorized as Normal: AHI<5, Mild sleep apnea: 5≤AHI<15, Moderate sleep apnea: 15≤AHI<30, Severe sleep apnea: AHI≥30. For each subject, the change in AHI will be calculated as the AHI at Month 3 minus the AHI at Baseline. A negative change value represents a lowering of the subjects AHI (an improvement, or reduction in sleep apnea). |
| Time Frame | 3 Month |
Outcome Measure Data
| Analysis Population Description |
|---|
| 2 of the 3 randomized participants did not complete the follow-up or provide outcome information. As there was only 1 participant that completed the outcome assessment, no statistical analysis will be presented. |
| Arm/Group Title | IT Group (SynchroMed/Intrathecal Morphine Sulfate) | Conventional Medical Management |
|---|---|---|
| Arm/Group Description | Subjects randomized to the IT group (Intrathecal morphine sulfate/SynchroMed Infusion System) will have a test injection or infusion of intrathecal morphine to check for pain control and make sure there are no negative reactions. If the test is successful, subjects in the IT group will have a pump and spinal catheter implanted. These subjects will stop using all other pain medications and start using only intrathecal morphine for pain control. SynchroMed Infusion System and Intrathecal Morphine Sulfate: Following a successful intrathecal test of morphine, IT morphine subjects will undergo surgery to implant the drug pump (SynchroMed) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control. | Subjects randomized to the CMM group will continue to use pain medications as prescribed by their doctor. Subjects randomized to CMM will be offered the option of pump implant following completion of the 3-month visit. |
| Measure Participants | 1 | 0 |
| Mean (Standard Deviation) [units on a scale] |
-10.4
(0)
|
Adverse Events
| Time Frame | throughout the study duration, from enrollment to 3 months follow-up after implant, an average of 4 months | |||
|---|---|---|---|---|
| Adverse Event Reporting Description | ||||
| Arm/Group Title | IT Group (SynchroMed/Intrathecal Morphine Sulfate) | Conventional Medical Management | ||
| Arm/Group Description | Subjects randomized to the IT group (Intrathecal morphine sulfate/SynchroMed Infusion System) will have a test injection or infusion of intrathecal morphine to check for pain control and make sure there are no negative reactions. If the test is successful, subjects in the IT group will have a pump and spinal catheter implanted. These subjects will stop using all other pain medications and start using only intrathecal morphine for pain control. SynchroMed Infusion System and Intrathecal Morphine Sulfate: Following a successful intrathecal test of morphine, IT morphine subjects will undergo surgery to implant the drug pump (SynchroMed) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control. | Subjects randomized to the CMM group will continue to use pain medications as prescribed by their doctor. Subjects randomized to CMM will be offered the option of pump implant following completion of the 3-month visit. | ||
All Cause Mortality |
||||
| IT Group (SynchroMed/Intrathecal Morphine Sulfate) | Conventional Medical Management | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | / (NaN) | / (NaN) | ||
Serious Adverse Events |
||||
| IT Group (SynchroMed/Intrathecal Morphine Sulfate) | Conventional Medical Management | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/3 (0%) | 0/0 (NaN) | ||
Other (Not Including Serious) Adverse Events |
||||
| IT Group (SynchroMed/Intrathecal Morphine Sulfate) | Conventional Medical Management | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 1/3 (33.3%) | 0/0 (NaN) | ||
| Infections and infestations | ||||
| Respiratory tract infection bacterial | 1/3 (33.3%) | 0/0 (NaN) | ||
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
The disclosure restrictions on the PI allow for the sponsor to review results communications prior to public release and to embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to sponsor for review. The sponsor is also allowed to require changes for technical correctness and to protect confidential information, copyrightable or patentable material; and when reasonably requested, extend the embargo up to an additional 90 days.
Results Point of Contact
| Name/Title | Mary Markert Sr Prin Clinical Research Specialist |
|---|---|
| Organization | Medtronic Neuromodulation |
| Phone | 763-526-8162 |
| mary.a.markert@medtronic.com |
- 1664 - CONVERT-TDD